FDA Updates Labeling on Febrile Seizure Risks i...

By João L. Carapinha

January 19, 2026

FDA Labeling Mandate on Febrile Seizure Risks In a significant update to vaccine safety protocols, the U.S. Food and Drug Administration (FDA) has required pediatric influenza vaccines t...
Guiding Principles for Ethical AI Integration in Drug Development
Obesity Medication Guidelines: Evidence-Based Approaches to Effective Treatment
Empowering Leaders at the Global Pharma Executive Course: Navigating Industry...
Johnson & Johnson’s Medicine Access Agreement: Paving the Way for ...
NICE Endorses Natalizumab RRMS Treatment Expansion for Refractory Cases
Bausch Health’s Strategic Growth in Latin American Pharmaceuticals Thro...
Johnson & Johnson’s EMA Application for Teclistamab Daratumumab Th...
Childhood Immunization Reforms: Aligning U.S. Schedules with Global Standards
Accelerating Tec-Dara Multiple Myeloma Therapy Review: A Game Changer for Pat...
AKEEGA BRCA2 Approval: Landmark FDA Decision for Precision Therapy in Aggress...
AI Governance Pharmaceuticals: Ensuring Ethical AI Integration in the Medicin...
Repurposing Off-Patent Medicines: Insights from the EU Pilot Initiative